Nivolumab and Ipilimumab Combination in Frontline mCRC
Michael J. Overman, MD, discusses recent data reported at the 2018 ESMO Congress for the frontline combination of nivolumab plus ipilimumab in microsatellite instability-high metastatic colorectal cancer.
Michael J. Overman, MD, professor of gastrointestinal and medical oncology at The University of Texas MD Anderson Cancer Center, discusses recent data reported at the 2018 ESMO Congress for the frontline combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) in microsatellite instability-high metastatic colorectal cancer.
At 1 year, the progression-free survival was approximately 80% and the majority of patients had a response. This is dramatic activity to see in the frontline, Overman notes.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
